Rucaparib [RUC4]
As maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy for a tumour which has a NEGATIVE status for a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation AND a NEGATIVE or UNKNOWN status for homologous recombination deficiency as defined by the presence of genomic instability where the following criteria have been met:
- This application for maintenance rucaparib is being made by and the first cycle of systemic anticancer therapy with rucaparib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- This patient has a proven histological diagnosis of predominantly high grade serous or high grade endometrioid or high grade clear cell ovarian, fallopian tube or primary peritoneal carcinoma. Please enter below as to which is the predominant histology in this patient
- high grade serous adenocarcinoma or
- high grade endometrioid adenocarcinoma or
- high grade clear cell carcinoma
- This patient has had germline and/or somatic (tumour) BRCA testing done and the result is negative. Please enter below the type of tissue on which BRCA mutation testing has been done:
- negative germline BRCA mutation test with somatic BRCA mutation test not done or
- negative somatic BRCA mutation test
- This patient’s tumour has either documented evidence of a negative status for homologous recombinant deficiency as determined by genomic instability testing by a NHS Genomic Laboratory Hub or the HRD test result is unknown. Please enter below the current status of HRD testing:
- negative HRD status
- unknown HRD status
- The patient has recently diagnosed FIGO stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma and has just completed 1st line platinum-based chemotherapy. Note: maintenance rucaparib in this 1st line maintenance indication is not funded for patients with recently diagnosed and treated stage I-IIC disease.
- One of the following scenarios applies to the surgical management of the patient in relation to the stage of the disease:
- the patient has stage III disease and had an upfront attempt at optimal cytoreductive surgery and had no visible residual disease at the end of surgery or
- the patient has stage III disease and had an upfront attempt at optimal cytoreductive surgery and had visible residual disease at the end of surgery or
- the patient has stage III disease and had an interval attempt at optimal cytoreductive surgery and had no visible disease at the end of surgery or
- the patient has stage III disease and had an interval attempt at optimal cytoreductive surgery and had visible disease at the end of surgery or
- the patient has stage III disease and has had a biopsy only with no upfront or interval attempt at cytoreductive surgery or
- the patient has stage IV disease and had an upfront attempt at optimal cytoreductive surgery and had no visible disease at the end of surgery or
- the patient has stage IV disease and had an upfront attempt at optimal cytoreductive surgery and had visible residual disease at the end of surgery or
- the patient has stage IV disease and had an interval attempt at optimal cytoreductive surgery and had no visible disease at the end of surgery or
- the patient has stage IV disease and had an interval attempt at optimal cytoreductive surgery and had visible disease at the end of surgery or
- the patient has stage IV disease and has had a biopsy only with no upfront or interval attempt at cytoreductive surgery
- The patient has been treated with platinum-based 1st line chemotherapy and has received a minimum of 4 cycles of platinum-based treatment.
- Whether the patient received induction bevacizumab as part of 1st line platinum-based treatment or not: Please indicate below whether induction bevacizumab was used in combination with the 1st line chemotherapy
- bevacizumab 7.5mg per Kg given in combination with platinum-based chemotherapy or
- bevacizumab 15mg per Kg given in combination with platinum-based chemotherapy or
- no bevacizumab used in combination with chemotherapy
- The patient is in response to the recently completed 1st line platinum-based chemotherapy and has achieved a partial or complete response to treatment according to the definitions given below and has no evidence of progressive disease on the post-treatment scan or a rising CA125 level. Please enter below as to which response assessment applies to this patient:
- achieved a complete response at the end of 1st line platinum-based chemotherapy i.e. has no measurable or non-measurable disease on the post-chemotherapy scan and the CA125 is normal or
- achieved a complete response at the end of 1st line platinum-based chemotherapy i.e. has no measurable or non-measurable disease on the post-chemotherapy scan and the CA125 has not decreased to within the normal range or
- achieved a partial response at the end of 1st line platinum-based chemotherapy i.e. has had a =30% reduction in measurable or non-measurable disease from the start of to the completion of 1st line chemotherapy and the CA125 is normal or
- achieved a partial response at the end of 1st line platinum-based chemotherapy i.e. has had a =30% reduction in measurable or non-measurable disease from the start of to the completion of 1st line chemotherapy and the CA125 has not decreased to within the normal range. (continued on next page)
CDF funded From: 01 February 2025 - anticipated to move to NHS funding: 09 June 2025
Additional information
Current Form Version
Note
The data on this page was produced using version 1.354 of the CDF list, downloaded from an archive of NHS England’s website on 14 March 2025 at 18:00.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.